To Evaluate the Safety and Efficacy of Intracranial Stent Assisted Endovascular Treatment of Intracranial Aneurysms

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorShanghai Wallaby Medical Technologies Co.,Inc.

About this trial

The purpose of this study is to assess safety and effectiveness of the pEGASUS stent system.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged from 18 to 80 years, male or female;

Patients diagnosed as wide-neck intracranial aneurysms by brain CTA/MRA/DSA (neck width≥4mm or bodyor a dome-to-neck ratio<2);

Parent vessel with a diameter of ≥2.5mm and ≤4.5mm;

Patients target aneurysm is planned to be embolized using intracranial stent assisted with coiling;

Disqualifiers

Patients who have contraindications to antiplatelet and/or anticoagulant therapy or do not start antiplatelet therapy in time before treatment.

Patients with anatomical structure is not suitable for endovascular treatment due to severe vascular tortuosity or stenosis shown by angiography.

Known to be allergic to Nitinol platinum alloy and angiographic agents.

Conditions that in the opinion of the investigators would prevent patients from completing the study, such as the expected survival period of active tumor less than 1-year, high-risk group of cerebral thrombosis, heart failure and atrial fibrillation.

Trial design

Design model

Single group

Treatments tested in this trial

  • pEGASUS Stent System

    Device

    Endovascular intervention with p64/p48 MW HPC pEGASUS Stent System was performed in patients diagnosed with intracranial aneurysms

Treatment groups

130 Participants
are divided into 1 treatment group
Group A: Test groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Aneurysm Occlusion of the Treated Target Lesion on 6 Month Angiography

Complete aneurysm occlusion (100% occlusion - Raymond Class 1) of the treated target lesion on 6 month angiography, in the absence of retreatment, or parent artery stenosis (\> 50%) at the target location.

Time frame
6 months
2

Rate of major ipsilateral stroke or neurological death

Any major ipsilateral stroke or neurological death

Time frame
12 months

Secondary outcomes

1

Technical success rate

Technical success is defined as the successful placement of pEGASUS stent system.

Time frame
Within 24 hours after surgery
2

Rate of successful occlusion

Aneurysm successful occlusion is defined as Raymond Grade I/II.

Time frame
Within 24 hours after surgery, 6 months, 12 months
3

Rate of complete occlusion

Aneurysm complete occlusion is defined as Raymond Grade I.

Time frame
Within 24 hours after surgery, 6 months, 12 months
4

Rate of good clinical prognosis

Good clinical prognosis means mRS 0\~2

Time frame
3 months, 6 months, 12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Shanghai Wallaby Medical Technologies Co.,Inc.

Lead sponsor

Phenox GmbH

Collaborator

Beijing Wallaby Medical Technologies Co.,Inc.

Collaborator